Investigational drug · Phase 2
HP518
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Metastatic Castration-resistant Prostate Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Dec 22, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "HP518"
First trial start
2023
Dec 26, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HP518", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Castration-resistant Prostate Cancer
Approved drugs for the same conditions: Prostate cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "HP518" as an intervention, largest first.
Hinova Pharmaceuticals Inc.Industry
NCT06155084 · 84 participants (planned) · Start Dec 26, 2023 · Primary completion Mar 2026
Drug: HP518 - Dose Escalation; HP518 - Dose Escalation and 1 more · For: Metastatic Castration-resistant Prostate Cancer
Sites: Hefei, China; Beijing, China; Chongqing, China · 27 sites in all
Hinova Pharmaceuticals Aus Pty LtdIndustry
NCT05252364 · 22 participants · Start Dec 14, 2021 · Primary completion Jan 22, 2024
Drug: HP518 - Dose Escalation; HP518 - Dose expansion · For: Metastatic Castration-resistant Prostate Cancer
Sites: Albury, Australia; Camperdown, Australia; Macquarie Park, Australia · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Constitutive androgen receptor activity sustains DNA replication programs in triple-negative breast cancer.
Li J, Yuan H, Chen K, et al. · Cell Death Dis 2026
- Phase 1 study of HP518, a PROTAC AR degrader in patients with mCRPC: results on safety, pharmacokinetics, and anti-tumor activity.
Azad AA, Gurney H, Underhill C, et al. · Invest New Drugs 2025
- Molecular glue degrader for tumor treatment.
Hu Y, Yan Y, Wang J, et al. · Front Oncol 2024
Also in development for Metastatic Castration-resistant Prostate Cancer
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- OpevesostatMK-5684, ODM-208Phase 37 trials
Merck & Co. · Prostate Cancer Metastatic, Malignant Neoplasm, Metastatic Castration-resistant Prostate Cancer (mCRPC)
- ONC-392Gotistobart, BNT316Phase 35 trials
OncoC4, Inc. · Non Small Cell Lung Cancer, Ovarian Cancer, Advanced Solid Tumor
- DB-1311BNT324Phase 34 trials
BioNTech SE · Metastatic Castration-resistant Prostate Cancer, Advanced Lung Cancer, Solid Tumors
- MevrometostatPF-06821497Phase 33 trials
Pfizer · Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer
- 177Lu-NYM032Phase 32 trials
Norroy Bioscience Co., LTD · Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
- XaluritamigAMG 509Phase 32 trials
Amgen · Metastatic Castration-resistant Prostate Cancer
- BMS-986365Phase 31 trial
Bristol Myers Squibb · Metastatic Castration-resistant Prostate Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.